Back
Top 3%
17.5%
Top 2%
11.7%
Top 0.3%
7.7%
Top 2%
6.4%
Top 77%
5.9%
#1
5.5%
Top 8%
5.0%
Top 3%
3.8%
Top 67%
3.8%
Top 0.5%
1.9%
Top 3%
1.9%
Top 3%
1.9%
Top 4%
1.3%
Top 17%
1.3%
Top 7%
1.3%
Top 4%
1.2%
Top 0.9%
1.2%
Top 10%
1.2%
Top 5%
1.0%
Top 5%
1.0%
Top 8%
0.7%
Top 10%
0.7%
Top 2%
0.7%
De Novo Design of Ultrahigh-Affinity Miniproteins Targeting PD-L1 for Non-Invasive Imaging: Preclinical Validation and First-in-Human Study
2025-08-12
oncology
Title + abstract only
View on medRxiv
Show abstract
De novo protein design is becoming a powerful tool for diagnostic and therapeutic agent development. However, direct evidence remains lacking for dynamic binding of de novo designed binders both in vivo and clinical settings. PD-L1, quantified via immunohistochemistry, represents the most widely validated, utilized, and accepted biomarker for PD-1/PD-L1 therapy. Due to the spatial heterogeneity and temporal dynamics of PD-L1 expression, this molecule represents an ideal target for exploring the ...
Predicted journal destinations
1
Nature Communications
483 training papers
2
Cancers
57 training papers
3
Clinical Cancer Research
22 training papers
4
Frontiers in Oncology
34 training papers
5
PLOS ONE
1737 training papers
6
Cell Reports
25 training papers
7
eLife
262 training papers
8
Proceedings of the National Academy of Sciences
100 training papers
9
Scientific Reports
701 training papers
10
Communications Biology
36 training papers
11
British Journal of Cancer
22 training papers
12
Cancer Medicine
17 training papers
13
BMC Cancer
21 training papers
14
JAMA Network Open
125 training papers
15
iScience
74 training papers
16
Journal of Clinical Investigation
50 training papers
17
Clinical Pharmacology & Therapeutics
19 training papers
18
Frontiers in Immunology
140 training papers
19
Cell Reports Medicine
49 training papers
20
International Journal of Molecular Sciences
39 training papers
21
Communications Medicine
63 training papers
22
Nature
58 training papers
23
Aging
18 training papers